JP2019518473A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019518473A5 JP2019518473A5 JP2019509457A JP2019509457A JP2019518473A5 JP 2019518473 A5 JP2019518473 A5 JP 2019518473A5 JP 2019509457 A JP2019509457 A JP 2019509457A JP 2019509457 A JP2019509457 A JP 2019509457A JP 2019518473 A5 JP2019518473 A5 JP 2019518473A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- binding molecule
- binding
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 44
- 239000002773 nucleotide Substances 0.000 claims description 21
- 125000003729 nucleotide group Chemical group 0.000 claims description 21
- 102000013691 Interleukin-17 Human genes 0.000 claims description 20
- 108050003558 Interleukin-17 Proteins 0.000 claims description 20
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 14
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 claims description 6
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 6
- 108090001005 Interleukin-6 Proteins 0.000 claims description 6
- 102000053162 human IL17A Human genes 0.000 claims description 6
- 102000057041 human TNF Human genes 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 101000998151 Homo sapiens Interleukin-17F Proteins 0.000 claims description 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 4
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 102000056946 human IL17F Human genes 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 230000000770 proinflammatory effect Effects 0.000 claims description 3
- 241000700199 Cavia porcellus Species 0.000 claims description 2
- 241000282567 Macaca fascicularis Species 0.000 claims description 2
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 101000648288 Sus scrofa Tumor necrosis factor Proteins 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000003013 cytotoxicity Effects 0.000 claims description 2
- 231100000135 cytotoxicity Toxicity 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 238000011534 incubation Methods 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 241000282412 Homo Species 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2016117140A RU2680011C2 (ru) | 2016-04-29 | 2016-04-29 | Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы |
| PCT/RU2016/050073 WO2017188850A1 (ru) | 2016-04-29 | 2016-12-02 | Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019518473A JP2019518473A (ja) | 2019-07-04 |
| JP2019518473A5 true JP2019518473A5 (https=) | 2020-01-23 |
| JP7104463B2 JP7104463B2 (ja) | 2022-07-21 |
Family
ID=60160914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019509457A Active JP7104463B2 (ja) | 2016-04-29 | 2016-12-02 | Ｉｌ－１７ａ、ｉｌ－１７ｆ、および他の炎症誘発性分子に対する三重特異的抗体 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11453717B2 (https=) |
| EP (1) | EP3450456A4 (https=) |
| JP (1) | JP7104463B2 (https=) |
| KR (1) | KR102900227B1 (https=) |
| CN (1) | CN109641953B (https=) |
| AU (1) | AU2016404449B2 (https=) |
| BR (1) | BR112018072294A2 (https=) |
| CA (1) | CA3022648A1 (https=) |
| CL (1) | CL2018003086A1 (https=) |
| CR (1) | CR20180557A (https=) |
| EC (1) | ECSP18088274A (https=) |
| MA (1) | MA43600B2 (https=) |
| MX (1) | MX2018013262A (https=) |
| NI (1) | NI201800110A (https=) |
| PH (1) | PH12018550180A1 (https=) |
| RU (1) | RU2680011C2 (https=) |
| WO (1) | WO2017188850A1 (https=) |
| ZA (1) | ZA201807924B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116059350A (zh) | 2015-10-27 | 2023-05-05 | Ucb生物制药有限责任公司 | 使用抗-il-17a/f抗体的治疗方法 |
| CN109970860A (zh) * | 2017-12-27 | 2019-07-05 | 信达生物制药(苏州)有限公司 | 三链抗体、其制备方法及其用途 |
| US20250074996A1 (en) * | 2021-02-19 | 2025-03-06 | Innovent Biologics (Suzhou) Co., Ltd. | ANTI-GPRC5DxBCMAxCD3 TRISPECIFIC ANTIBODY AND USE THEREOF |
| WO2025238133A1 (en) * | 2024-05-17 | 2025-11-20 | UCB Biopharma SRL | Multispecific antibody with binding specificity for il-11 and il-17 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| US6274711B1 (en) | 1993-06-14 | 2001-08-14 | Inserm, Institut National De La Sante Et De La Recherche Medicale | Purified mammalian CTLA-8 antigens and related reagents |
| US20020177188A1 (en) | 1998-05-15 | 2002-11-28 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
| GB0013810D0 (en) * | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
| US20070160576A1 (en) | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
| HUE026260T2 (en) | 2003-11-21 | 2016-06-28 | Ucb Biopharma Sprl | A method for treating multiple sclerosis by inhibiting IL-17 activity |
| BRPI0510617A (pt) | 2004-05-03 | 2007-10-30 | Schering Corp | uso de expressão de il-17 para prever inflamação de pele; processos de tratamento |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| US7790163B2 (en) * | 2006-03-10 | 2010-09-07 | Zymogenetics, Inc. | Antibodies that bind both IL-17A and IL-17F and methods of using the same |
| US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
| RU2474588C2 (ru) | 2008-05-05 | 2013-02-10 | Новиммун Са | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения |
| TWI541021B (zh) * | 2009-03-05 | 2016-07-11 | 艾伯維有限公司 | Ｉｌ－１７結合蛋白 |
| ME02734B (me) * | 2011-01-14 | 2017-10-20 | Ucb Biopharma Sprl | Antitelo koje vezuje il-17a i il-17f |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| RU2014121043A (ru) * | 2011-10-24 | 2015-12-10 | Эббви Инк. | Биспецифические иммуносвязывающие средства, направленные против tnf и il-17 |
| TW201444867A (zh) | 2013-03-08 | 2014-12-01 | Lilly Co Eli | 抗ｔｎｆ－抗ｉｌ－１７雙特異性抗體 |
| EP3027649B1 (en) | 2013-08-01 | 2020-04-01 | F.Hoffmann-La Roche Ag | Tnfa-il-17 bispecific antibodies |
| RU2609627C2 (ru) * | 2014-09-26 | 2017-02-02 | Закрытое Акционерное Общество "Биокад" | Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh |
| GB201522391D0 (en) * | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibody molecules |
-
2016
- 2016-04-29 RU RU2016117140A patent/RU2680011C2/ru active
- 2016-12-02 EP EP16900649.1A patent/EP3450456A4/en active Pending
- 2016-12-02 MA MA43600A patent/MA43600B2/fr unknown
- 2016-12-02 WO PCT/RU2016/050073 patent/WO2017188850A1/ru not_active Ceased
- 2016-12-02 JP JP2019509457A patent/JP7104463B2/ja active Active
- 2016-12-02 CR CR20180557A patent/CR20180557A/es unknown
- 2016-12-02 MX MX2018013262A patent/MX2018013262A/es unknown
- 2016-12-02 US US16/097,562 patent/US11453717B2/en active Active
- 2016-12-02 CA CA3022648A patent/CA3022648A1/en active Pending
- 2016-12-02 AU AU2016404449A patent/AU2016404449B2/en active Active
- 2016-12-02 KR KR1020187034250A patent/KR102900227B1/ko active Active
- 2016-12-02 BR BR112018072294-4A patent/BR112018072294A2/pt active Search and Examination
- 2016-12-02 CN CN201680086630.2A patent/CN109641953B/zh active Active
-
2018
- 2018-10-29 PH PH12018550180A patent/PH12018550180A1/en unknown
- 2018-10-29 CL CL2018003086A patent/CL2018003086A1/es unknown
- 2018-10-29 NI NI201800110A patent/NI201800110A/es unknown
- 2018-11-23 ZA ZA2018/07924A patent/ZA201807924B/en unknown
- 2018-11-27 EC ECSENADI201888274A patent/ECSP18088274A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110799539B (zh) | 抗4-1bb抗体及其制备和使用方法 | |
| CN108699136B (zh) | 结合cd3和psma的异二聚抗体 | |
| CN108367075B (zh) | 4-1bb结合蛋白及其用途 | |
| CN114502591B (zh) | 靶向bcma的抗体、双特异性抗体及其用途 | |
| JP2021524267A5 (https=) | ||
| JP5818804B2 (ja) | ヒトｉｌ−２２ｒａに対するヒト化抗体 | |
| TWI815306B (zh) | PD-1/TGF-beta四價雙特異性抗體、其製備方法和用途 | |
| CN114746440A (zh) | 新型多肽复合物 | |
| CN115397852B (zh) | 工程化抗il-2抗体 | |
| JP2016509014A (ja) | 新規の多特異的構成物 | |
| CN111615519B (zh) | 结合人il-5的单克隆抗体、其制备方法和用途 | |
| CN108473568A (zh) | 对TNF-α、IL-17A和IL-17F具有特异性的多特异性抗体分子 | |
| AU2019233511B2 (en) | Anti C-MET antibodies | |
| WO2021018035A1 (zh) | 人源化抗il17a抗体及其应用 | |
| JP2023510844A5 (https=) | ||
| KR20250017233A (ko) | 항-bdca2 항체 및 이의 용도 | |
| JP2019518473A5 (https=) | ||
| KR20220030934A (ko) | 항-gal9 면역-억제 결합 분자 | |
| JP2022522815A (ja) | Ｔｓｇ－６抗体およびその用途 | |
| RU2016117140A (ru) | Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы | |
| WO2019230869A1 (ja) | 抗ヒトｔｌｒ７抗体 | |
| WO2023125561A1 (zh) | 靶向tigit的抗体和双特异性抗体及其应用 | |
| TW202309076A (zh) | 用於治療α-突觸核蛋白病之抗體 | |
| CN114573703A (zh) | 一种t细胞衔接器治疗剂的开发和应用 | |
| CN118159562A (zh) | 靶向ccr2的抗体 |